Company profile ATNM

Actinium Pharmaceuticals Inc
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and ce...rtain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o Show More
Quarter analysis & expected interestLast update: February 08 2024 15:35:16.

After 39 days of this quarter the interest is at 17.0. Based on that we can calculate that during remaining 52 days it will total up to 40.0.
Actinium Pharmaceuticals expected interest is significantly lower compared to same quarter last year (-73.5%) but similar to previous quarter.

YearQ1Q2Q3Q4
201993
100
7.5% QoQ
76
-24.0% QoQ
91
19.7% QoQ
2020 125
34.4% YoY 37.4% QoQ
368
268.0% YoY 194.4% QoQ
519
582.9% YoY 41.0% QoQ
126
38.5% YoY -75.7% QoQ
2021 64
-48.8% YoY -49.2% QoQ
109
-70.4% YoY 70.3% QoQ
49
-90.6% YoY -55.0% QoQ
73
-42.1% YoY 49.0% QoQ
2022 41
-35.9% YoY -43.8% QoQ
75
-31.2% YoY 82.9% QoQ
41
-16.3% YoY -45.3% QoQ
67
-8.2% YoY 63.4% QoQ
2023 151
268.3% YoY 125.4% QoQ
80
6.7% YoY -47.0% QoQ
116
182.9% YoY 45.0% QoQ
41
-38.8% YoY -64.7% QoQ
2024 17
-88.7% YoY -58.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Actinium Pharmaceuticals search interestLast update: February 08 2024 15:35:16.
Correlation coefficient between keyword and revenue is -0.39
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:35:17.

The average 5 years interest of Actinium Pharmaceuticals was 9.28 per week.
The last year interest of Actinium Pharmaceuticals compared to the last 5 years has changed by -29.74%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -18.7%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals cancer treatment to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals cancer treatment search interest

There is not enough data for Actinium Pharmaceuticals cancer treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals cancer treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals Iomab-B to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals Iomab-B search interest

There is not enough data for Actinium Pharmaceuticals Iomab-B to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals Iomab-B to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals targeted radiotherapies to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals targeted radiotherapies search interest

There is not enough data for Actinium Pharmaceuticals targeted radiotherapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals targeted radiotherapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals clinical trials to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals clinical trials search interest

There is not enough data for Actinium Pharmaceuticals clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:35:22.

After 39 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 52 days it will total up to 47.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201973
126
72.6% QoQ
99
-21.4% QoQ
69
-30.3% QoQ
2020 118
61.6% YoY 71.0% QoQ
326
158.7% YoY 176.3% QoQ
539
444.4% YoY 65.3% QoQ
137
98.6% YoY -74.6% QoQ
2021 72
-39.0% YoY -47.4% QoQ
87
-73.3% YoY 20.8% QoQ
34
-93.7% YoY -60.9% QoQ
119
-13.1% YoY 250.0% QoQ
2022 17
-76.4% YoY -85.7% QoQ
41
-52.9% YoY 141.2% QoQ
38
11.8% YoY -7.3% QoQ
106
-10.9% YoY 178.9% QoQ
2023 78
358.8% YoY -26.4% QoQ
18
-56.1% YoY -76.9% QoQ
65
71.1% YoY 261.1% QoQ
51
-51.9% YoY -21.5% QoQ
2024 20
-74.4% YoY -60.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Actinium Pharmaceuticals stock search interestLast update: February 08 2024 15:35:21.
Correlation coefficient between keyword and revenue is -0.33
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:35:23.

The average 5 years interest of Actinium Pharmaceuticals stock was 8.56 per week.
The last year interest of Actinium Pharmaceuticals stock compared to the last 5 years has changed by -57.13%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -53.25%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:35:29.

After 39 days of this quarter the interest is at 12.0. Based on that we can calculate that during remaining 52 days it will total up to 28.0.
Actinium Pharmaceuticals -stock -company expected interest is significantly lower compared to previous quarter (-67.1%) and same quarter last year (-84.7%).

YearQ1Q2Q3Q4
2019123
146
18.7% QoQ
100
-31.5% QoQ
227
127.0% QoQ
2020 199
61.8% YoY -12.3% QoQ
410
180.8% YoY 106.0% QoQ
540
440.0% YoY 31.7% QoQ
140
-38.3% YoY -74.1% QoQ
2021 19
-90.5% YoY -86.4% QoQ
174
-57.6% YoY 815.8% QoQ
69
-87.2% YoY -60.3% QoQ
70
-50.0% YoY 1.4% QoQ
2022 109
473.7% YoY 55.7% QoQ
113
-35.1% YoY 3.7% QoQ
101
46.4% YoY -10.6% QoQ
90
28.6% YoY -10.9% QoQ
2023 183
67.9% YoY 103.3% QoQ
160
41.6% YoY -12.6% QoQ
143
41.6% YoY -10.6% QoQ
85
-5.6% YoY -40.6% QoQ
2024 12
-93.4% YoY -85.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Actinium Pharmaceuticals -stock -company search interestLast update: February 08 2024 15:35:29.
Correlation coefficient between keyword and revenue is -0.33
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:35:30.

The average 5 years interest of Actinium Pharmaceuticals -stock -company was 12.31 per week.
The last year interest of Actinium Pharmaceuticals -stock -company compared to the last 5 years has changed by -19.42%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -23.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals reviews to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals reviews search interest

There is not enough data for Actinium Pharmaceuticals reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals CAR T-cell therapy to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals CAR T-cell therapy search interest

There is not enough data for Actinium Pharmaceuticals CAR T-cell therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals CAR T-cell therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals CD33 to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals CD33 search interest

There is not enough data for Actinium Pharmaceuticals CD33 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals CD33 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ATNM
Earnings date: 2024-03-31 After close
Company name: Actinium Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-20T08:00:00-04:00

PR Newswire
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

2026-10-20T07:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

2026-10-16T17:00:00-04:00

PR Newswire
Actinium Pharmaceuticals Announces Inducement Grants to New Employees

2026-10-16T08:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

2026-10-16T07:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

2026-10-15T08:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

2026-10-15T07:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

2026-09-04T17:05:00-04:00

PR Newswire
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

2026-08-14T17:02:00-04:00

PR Newswire
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

2026-06-03T08:00:00-04:00

PR Newswire
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

2026-06-03T07:25:00-04:00

PR Newswire
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

2026-06-01T08:00:00-04:00

PR Newswire
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

2026-06-01T07:00:00-04:00

PR Newswire
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

2026-05-29T17:31:00-04:00

PR Newswire
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

2026-05-29T17:30:00-04:00

PR Newswire
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice